Cumberland Pharmaceuticals
CPIX
41 hedge funds and large institutions have $30.2M invested in Cumberland Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
25% more capital inflows, than outflows
Capital inflows: $1.84M | Capital outflows: $1.47M
3% more funds holding
Funds holding: 40 → 41 (+1)
0.41% more ownership
Funds ownership: 33.48% → 33.88% (+0.41%)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.54M |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
+$69.9K |
| 3 |
BlackRock Institutional Trust
San Francisco,
California
|
+$61.6K |
| 4 |
Renaissance Technologies
New York
|
+$51.6K |
| 5 |
Ancora Advisors
Cleveland,
Ohio
|
+$18.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ariel Investments
Chicago,
Illinois
|
-$1.17M |
| 2 |
United Capital Financial Advisors
Irving,
Texas
|
-$139K |
| 3 |
Morgan Stanley
New York
|
-$65.1K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$38.1K |
| 5 |
Invesco
Atlanta,
Georgia
|
-$13K |
CPIX Hedge Fund Activity: Q4 2016 in Review
41 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q4 2016, worth a combined $30.2M — up 11% from $27.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CPIX positions and 1 closed out — a net gain of 2 holders — while 12 added to existing stakes and 14 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $1.54M. The largest seller was Ariel Investments, cutting an estimated $1.17M.
- 41 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q4 2016, up from 40 in Q3 2016.
- Funds reported $30.2M of Cumberland Pharmaceuticals stock for Q4 2016, up 11% quarter-over-quarter.
- 3 funds opened new Cumberland Pharmaceuticals positions in Q4 2016 and 1 closed out, a net change of +2 holders.
- The largest Cumberland Pharmaceuticals buyer in Q4 2016 was Stonepine Capital Management, an estimated $1.54M added.
- The largest Cumberland Pharmaceuticals seller in Q4 2016 was Ariel Investments, an estimated $1.17M sold.
Based on aggregated 13F filings for Q4 2016.